AVEO - AVEO Pharmaceuticals, Inc.
2.33 +0.06 (2.64%)
After hours: 7:57PM EDT
| Previous Close | 2.15 |
| Open | 2.20 |
| Bid | 2.27 x 1000 |
| Ask | 2.41 x 900 |
| Day's Range | 2.11 - 2.37 |
| 52 Week Range | 1.86 - 3.59 |
| Volume | 4,774,587 |
| Avg. Volume | 2,307,910 |
| Market Cap | 355.97M |
| Beta (3Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.32 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- Business Wire•2 days ago
AVEO Oncology and EUSA Pharma Announce Updated Interim Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
AVEO Oncology (AVEO) and EUSA Pharma today announced the presentation of updated interim results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA®) in combination with intravenous (IV) nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced or metastatic renal cell carcinoma. The results were presented today at European Society of Medical Oncology (ESMO) 2018 Annual Congress, in a poster presentation titled “TiNivo: Tivozanib Combined with Nivolumab: Safety and Efficacy in Patients with Metastatic Renal Cell Carcinoma (mRCC)” (Presentation 878P).
- GlobeNewswire•6 days ago
Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Motley Fool•13 days ago
Why AVEO Pharmaceuticals, Inc. Stock Perked Up in September
AVEO is close to a key clinical readout that could prove to be a major catalyst for its stock.
- Zacks•15 days ago
Do Options Traders Know Something About AVEO Stock We Don't?
Investors need to pay close attention to AVEO stock based on the movements in the options market lately.
- Business Wire•15 days ago
AVEO Oncology to Present Updated Interim Results from the Phase 2 Portion of the TiNivo Study of Tivozanib and Nivolumab (OPDIVO®) in RCC at the ESMO 2018 Annual Congress
AVEO Oncology (AVEO) today announced that updated interim data from the Phase 2 portion of the TiNivo trial of tivozanib and nivolumab (OPDIVO®) in advanced renal cell carcinoma will be presented at the European Society of Medical Oncology (ESMO) 2018 Annual Congress being held October 19-23, 2018 in Munich, Germany. The TiNivo study is a Phase 1b/2 multicenter trial of oral tivozanib (FOTIVDA®) in combination with intravenous nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of metastatic renal cell carcinoma (mRCC). The accepted abstract, which includes results from a poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in January, is available via the ESMO 2018 Annual Congress website.
- Business Wire•23 days ago
AVEO Oncology Announces Initiation of Topline Analysis of Phase 3 TIVO-3 Trial
AVEO Oncology (AVEO) today announced that it has initiated topline analysis of the phase 3 TIVO-3 clinical trial on the unanimous recommendation of the independent TIVO-3 Study Steering Committee, and after notice to the FDA. The TIVO-3 trial is the Company’s randomized, controlled, multi-center, open-label study to compare FOTIVDA® (tivozanib) to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). The Company expects to complete data analysis and report topline results from the study in approximately 6 weeks.
- Zacks•27 days ago
AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 6.4% in Session
AVEO Pharmaceuticals (AVEO) shares rose more than 6% in the last trading session, amid huge volumes.
- ACCESSWIRE•28 days ago
Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Heron Therapeutics
NEW YORK, NY / ACCESSWIRE / September 26, 2018 / U.S. equities were mixed on Tuesday as concerns of a potential trade war linger and investors look forward to details from the upcoming Fed monetary policy ...
- Motley Fool•28 days ago
Why AVEO Pharmaceuticals Inc. Rocketed Higher Today
Hint: It had nothing to do with the press release. The biotech is presenting at a few upcoming conferences, but only one really matters.
- Business Wire•29 days ago
AVEO Oncology to Participate in Upcoming Conferences
A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need.
- Zacks•last month
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
- Zacks•2 months ago
AVEO (AVEO) Up 25.3% Since Last Earnings Report: Can It Continue?
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool•2 months ago
Here's Why AVEO Pharmaceuticals Inc. Jumped 40% Higher in August
Investors jump in ahead of expected clinical trial data.
- InvestorPlace•2 months ago
Aveo Stock Breaks Out After Strong Drug Results and a Modest Offering
When a biotech company prices a common stock offering, diluting existing shareholders, the stock typically falls. Around $11.1 million of its net income is due to a non-cash gain related to the fall in the fair value of the 2016 private placement warrant liability.
- Business Wire•2 months ago
AVEO Oncology to Participate in Upcoming Conferences
A live webcast of Mr. Bailey’s presentation at the Rodman & Renshaw conference can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and AVEO Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 27, 2018 / U.S. equities closed up on Friday following Federal Reserve Chairman Jerome Powell's speech, which confirmed the Federal Reserve will gradually normalize monetary ...
- GlobeNewswire•2 months ago
New Research: Key Drivers of Growth for Teradata, Boyd Gaming, Intrepid Potash, MSG Networks, AVEO Pharmaceuticals, and NetScout — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Teradata ...
- Business Wire•2 months ago
AVEO Announces Pricing of $5.7 Million Public Offering of Common Stock
AVEO Pharmaceuticals, Inc. (AVEO) today announced that it has priced an underwritten public offering of 2,500,000 shares of common stock at a price to the public of $2.26 per share, the closing price as of yesterday, August 16, 2018, which would result in aggregate gross proceeds of approximately $5.7 million before underwriting discounts. All of the shares in the offering are to be sold by AVEO. AVEO has also granted the underwriter a 30-day option to purchase up to an additional 375,000 shares of common stock on the same terms and conditions.
- Benzinga•2 months ago
The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 16) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Eli Lilly And ...
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Array BioPharma and AVEO Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 17, 2018 / U.S. markets bounced back on Thursday after Walmart and Cisco reported upbeat quarterly earnings. The Dow Jones Industrial Average jumped 1.58 percent to close ...
- Business Wire•2 months ago
AVEO Announces Proposed Offering of Common Stock
AVEO Pharmaceuticals, Inc. (AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The net proceeds of the offering are expected to be used for working capital and general corporate purposes, including development and pre-commercial expenses incurred in connection with the ongoing Phase 3 clinical trial of tivozanib in the third-line treatment of patients with advanced renal cell carcinoma (“aRCC”) as well as the ongoing Phase 1b/2 clinical trial of tivozanib in combination with OPDIVO® (nivolumab).
- Business Wire•2 months ago
AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
AVEO Oncology (AVEO) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences’ Investigational New Drug (IND) Application for a Phase Ib/III clinical trial of CAN017 (AV-203), AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate, in esophageal squamous cell cancer (ESCC). Under the terms of a March 2016 agreement, the acceptance of this IND triggers a $2 million milestone payment to AVEO from CANbridge Life Sciences. CANbridge licensed worldwide rights, excluding the United States, Canada, and Mexico, to AV-203 from AVEO and AVEO is eligible to receive up to $40 million in potential additional development and regulatory milestone payments and up to $90 million in potential commercial milestone payments, assuming the successful achievement of specified development, regulatory and commercialization objectives.
- Zacks•3 months ago
AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss
AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.
- Zacks•3 months ago
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of -150.00% and -67.93%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
AVEO: 2Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had profit of 6 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The results did not meet Wall Street expectations. ...
